Pfizer(PFE) is having a Dividend Yield of 3.82% with the Annual cash Dividend per share of $1.2. The last quarter cash dividend per share pay out was $0.3. Pfizer has a 5 year average dividend yield of 3.49% and the stock has a Indicated annual dividend of $1.28. Pfizer(PFE) formally announced its most recent dividend on December 13, 2016 with a Dividend per share of $0.32. The new indicated annual dividend based on announced dividend per share is $1.28. The dividend yield based on the forward looking indicated annual dividend is 3.82%. Pfizer(PFE) has the most recent dividend payout ratio of 0.5 with a 5-year average payout ratio of 0.46. Companys change in pay out ratio when compared to the last 5 years average pay out ratio has been 0.04. The 5 year historical dividend growth of Pfizer(PFE) is at the rate of 7.74% while the R-Squared dividend growth is 0.96. If the value of R-Square is close to one, it indicates a perfect fit and the higher value conforms to the regression line while data close to zero indicates the opposite.
Pfizer, Inc. (NYSE:PFE) rose 0.33% or 0.11 points on Thursday and made its way into the gainers of the day. After trading began at $33.45 the stock was seen hitting $33.885 as a peak level and $33.22 as the lowest level. The stock ended up at $33.62. The daily volume was measured at 38,332,300 shares. The 52-week high of the share price is $37.39 and the 52-week low is $28.74. The company has a market cap of $204,018 million. Shares of Pfizer Inc. rose by 3.83% in the last five trading days and 6.03% for the last 4 weeks. Pfizer Inc. is up 5.38% in the last 3-month period. Year-to-Date the stock performance stands at 4.56%.
Currently the company Insiders own 0.07% of Pfizer, Inc. shares according to the proxy statements. Institutional Investors own 69.53% of Pfizer, Inc. shares. During last six month period, the net percent change held by insiders has seen a change of -8.19%. Company has reported several Insider transactions to the SEC, on Nov 10, 2016, Anthony J Maddaluna (Executive Vice President) sold 10,000 shares at 33.00 per share price.On Nov 7, 2016, Albert Bourla (Group President) sold 18,390 shares at 30.05 per share price.On May 27, 2016, Frank A Damelio (Executive Vice President) sold 100,000 shares at 34.49 per share price.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Pfizer was Initiated by Guggenheim to Neutral on Dec 2, 2016.
Pfizer Last issued its quarterly earnings results on Jan 31, 2017. The company reported $0.47 EPS for the quarter, missing the analyst consensus estimate by $ -0.04. Analyst had a consensus of $0.51. The company had revenue of $13627.00 million for the quarter, compared to analysts expectations of $13689.67 million. The companys revenue was down -3.0 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.53 EPS.
Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Companys diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and consumer healthcare products. Pfizers Animal Health business unit discovers, develops and sells products for the prevention and treatment of diseases in livestock and companion animals. It sells its products to wholesalers, distributors, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, veterinarians, livestock producers, and grocery and convenience stores. Pfizer Inc. is headquartered in New York.